<?xml version='1.0' encoding='utf-8'?>
<document id="26959999"><sentence text="Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters."><entity charOffset="42-57" id="DDI-PubMed.26959999.s1.e0" text="Oligonucleotide" /><entity charOffset="63-84" id="DDI-PubMed.26959999.s1.e1" text="2'-O-(2-Methoxyethyl)" /><pair ddi="false" e1="DDI-PubMed.26959999.s1.e0" e2="DDI-PubMed.26959999.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26959999.s1.e0" e2="DDI-PubMed.26959999.s1.e1" /></sentence><sentence text="ISIS 141923 is a model compound of 2'-O-(2-methoxyethyl) (2'-MOE) modified antisense oligonucleotides (ASOs)"><entity charOffset="85-101" id="DDI-PubMed.26959999.s2.e0" text="oligonucleotides" /><entity charOffset="103-107" id="DDI-PubMed.26959999.s2.e1" text="ASOs" /><pair ddi="false" e1="DDI-PubMed.26959999.s2.e0" e2="DDI-PubMed.26959999.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26959999.s2.e0" e2="DDI-PubMed.26959999.s2.e1" /></sentence><sentence text=" The purpose of this study is to determine whether ISIS 141923 is a substrate or an inhibitor against a panel of nine major uptake or efflux drug transporters, namely breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), organic anion transporter (OAT)1, OAT3, organic cation transporter (OCT)1, OCT2, organic anion transporting polypeptide 1B (OATP1B)1, OATP1B3, and bile salt export pump (BSEP), in vitro" /><sentence text=" The uptake test system for transporters in the solute carrier (SLC) family (OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3) was studied in Madin-Darby canine kidney (MDCK)-II cells transfected to express the transporters of interest" /><sentence text=" BCRP was studied using carcinoma colon-2 (Caco-2) cells with endogenously expressed BCRP" /><sentence text=" P-gp transporter was studied in MDCK-multi-drug resistance 1 (MDR1) cells, while BSEP was studied using Spodoptera frugiperda 9 (Sf9) membrane vesicles containing human BSEP" /><sentence text=" The ISIS 141293 concentrations evaluated were 10 and 100 μM for the substrate and inhibition study, respectively" /><sentence text=" Cellular uptake of ISIS 141923 was analyzed using a high performance liquid chromatography-mass spectrometry method, while concentrations of known substrates (used as positive controls) of each transporters evaluated were determined by radiometric detection" /><sentence text=" At 10 μM ISIS 141923, there was no significant transporter-mediated uptake of ISIS 141923 (P &gt; 0" /><sentence text="05) in the SLC family, and the efflux ratios were not above 2" /><sentence text="0 for either BCRP or P-gp" /><sentence text=" Therefore, no transporter-mediated uptake of ISIS 141923 was observed by any of the nine transporters studied" /><sentence text=" At 100 μM ISIS 141923, the % inhibition was in the range of -16" /><sentence text="0% to 19" /><sentence text="0% for the nine transporters evaluated" /><sentence text=" Therefore, ISIS 141923 is not considered as an inhibitor of the nine transporters studied" /><sentence text=" Overall, the results from this study suggest that it is unlikely that ISIS 141923 or similar 2'-MOE ASOs would interact with small molecule drugs either as a victim (substrate) or perpetrator (inhibitor) of major transporters in humans"><entity charOffset="94-100" id="DDI-PubMed.26959999.s17.e0" text="2'-MOE" /><entity charOffset="101-106" id="DDI-PubMed.26959999.s17.e1" text="ASOs" /><pair ddi="false" e1="DDI-PubMed.26959999.s17.e0" e2="DDI-PubMed.26959999.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26959999.s17.e0" e2="DDI-PubMed.26959999.s17.e1" /></sentence><sentence text=" The results from available clinical drug-drug interaction studies conducted with this class of compounds to date are also supportive of this conclusion" /><sentence text="" /></document>